Author

Walter Reinisch

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Walter Reinisch  et al.

A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS
A TRANSCRIPTOME-DEPENDENT PROGNOSTIC MODEL OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS

Walter Reinisch  et al.

ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC RESPONSE AND LONG-TERM CLINICAL OUTCOMES: RESULTS FROM PHASE 2 MIRIKIZUMAB TRIAL IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE
ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC RESPONSE AND LONG-TERM CLINICAL OUTCOMES: RESULTS FROM PHASE 2 MIRIKIZUMAB TRIAL IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE

Walter Reinisch  et al.

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Walter Reinisch  et al.

SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY
SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY

Walter Reinisch  et al.

BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL
BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL

Walter Reinisch  et al.

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Walter Reinisch  et al.

EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES
EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES

Walter Reinisch  et al.

EFFECT OF UPADACITINIB ON EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF UPADACITINIB ON EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Walter Reinisch  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Walter Reinisch  et al.

WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS
WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS

Walter Reinisch  et al.

COMPARATIVE BIOAVAILABILITY OF NOVEL CYCLOSPORINE FORMULATIONS VERSUS REFERENCE ORAL CYCLOSPORINE IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS
COMPARATIVE BIOAVAILABILITY OF NOVEL CYCLOSPORINE FORMULATIONS VERSUS REFERENCE ORAL CYCLOSPORINE IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS

Walter Reinisch  et al.

MEASUREMENT OF ULCERATED AND AFFECTED SURFACE OF THE COLON MAY PROVIDE MORE INSIGHT INTO RESPONSE COMPARED TO ENDOSCOPIC MAYO SCORE - A POST HOC ANALYSIS
MEASUREMENT OF ULCERATED AND AFFECTED SURFACE OF THE COLON MAY PROVIDE MORE INSIGHT INTO RESPONSE COMPARED TO ENDOSCOPIC MAYO SCORE - A POST HOC ANALYSIS

Walter Reinisch  et al.

RESTORATION OF MICROBIOME COMPOSITION AND INCREASED BUTYRATE PRODUCTION ARE ASSOCIATED WITH RESPONSE TO SYSTEMIC CORTICOSTEROIDS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS
RESTORATION OF MICROBIOME COMPOSITION AND INCREASED BUTYRATE PRODUCTION ARE ASSOCIATED WITH RESPONSE TO SYSTEMIC CORTICOSTEROIDS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS

Walter Reinisch  et al.

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Walter Reinisch  et al.

USTEKINUMAB IMPROVES EXTRA-INTESTINAL MANIFESTATIONS IN CROHN'S DISEASE: A POST HOC ANALYSIS OF THE UNITI STUDIES
USTEKINUMAB IMPROVES EXTRA-INTESTINAL MANIFESTATIONS IN CROHN'S DISEASE: A POST HOC ANALYSIS OF THE UNITI STUDIES

Walter Reinisch  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Walter Reinisch  et al.

MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS
MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS

Walter Reinisch  et al.

PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC
PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC

Walter Reinisch  et al.

ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY
ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY

Walter Reinisch  et al.

Item 21 - 40 / 57
1
2
3